Hamlet Pharma enters a new development phase

Hamlet Pharma has successfully established a strong position with broad expertise in the cancer field. Now, the company has solved the GMP production issue, and reached an important milestone for future clinical trials.

The protein-lipid complex HAMLET represents a new type of tumoricidal biological, with broad effects against cancers of different origin. The therapeutic potential is further enhanced by a high degree of specificity for tumor tissue. Now research efforts have identified a tumoricidal peptide motif in HAMLET and devised a new technology for large-scale production of active compound. The technology is covered by an approved US patent and additional patents are pending in both Europe and the US.

Due to the rapid scientific development, Hamlet Pharma can apply for use of peptide complexes as “second-generation drugs” for use in Phase II clinical trials. The peptide-based technology will also be adequate for large-scale production, sufficient for future phase III trials. The benefits include precision, lower cost than recombinant production of the entire HAMLET complex and a less complex process for GMP approval. In addition, the patent life of the peptide complexes is significantly longer. The peptide production technology will also make it possible for the company to explore additional clinical indications and to explore out-licensing of selected therapeutic areas.

“It is fascinating to follow how the peptide complex makes its way into the nuclei of tumor cells and ensures that the cells are killed” says Professor Catharina Svanborg, founder and chairman of the board of Hamlet Pharma.

The Company and HAMLET has now taken an important step towards an approved drug” says Mats Persson, CEO of Hamlet Pharma.

For more information, please contact
Catharina Svanborg, Chairman of the board, Hamlet Pharma, +46-709 42 65 49
Catharina.svanborg@med.lu.se
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
mats.persson@hamletpharma.com

About Hamlet Pharma
Hamlet Pharma AB owns and develops a new technology to kill cancer cells without harming healthy tissues. The HAMLET technology is focused around the HAMLET family of tumoricidal protein-lipid complexes, formed by naturally occurring molecules from human milk and extended to include recombinant variants of the natural substance. HAMLET has validated therapeutic efficacy in clinical studies and animal models, and in many different cellular models of human cancer. HAMLET will now be developed further for Phase II clinical trials, to verify the positive proof of concept studies. Hamlet Pharma AB shares are listed at AktieTorget. HAMLET is an abbreviation for Human Alpha-lactalbumin Made LEthal to Tumor cells.